|
Published by: Global Markets Direct
Published: Aug. 31, 2012 - 107 Pages
Table of Contents- Introduction
- Global Markets Direct Report Coverage
- Gouty Arthritis (Gout) Overview
- Therapeutics Development
- An Overview of Pipeline Products for Gouty Arthritis (Gout)
- Gouty Arthritis (Gout) Therapeutics under Development by Companies
- Gouty Arthritis (Gout) Therapeutics under Investigation by Universities/Institutes
- Late Stage Products
- Comparative Analysis
- Mid Clinical Stage Products
- Comparative Analysis
- Early Clinical Stage Products
- Comparative Analysis
- Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Gouty Arthritis (Gout) Therapeutics – Products under Development by Companies
- Gouty Arthritis (Gout) Therapeutics – Products under Investigation by Universities/Institutes
- Companies Involved in Gouty Arthritis (Gout) Therapeutics Development
- Novartis AG
- Kissei Pharmaceutical Co., Ltd.
- Savient Pharmaceuticals, Inc.
- Addex Pharmaceuticals
- Ardea Biosciences, Inc.
- BioCryst Pharmaceuticals, Inc.
- SANWA KAGAKU KENKYUSHO CO.,LTD.
- Regeneron Pharmaceuticals, Inc.
- XOMA Ltd.
- LG Life Sciences, Ltd
- Metabolex, Inc
- Wellstat Therapeutics Corporation
- Opsona Therapeutics Ltd.
- PLx Pharma Inc.
- Nuon Therapeutics, Inc.
- Polaris Group
- Eleven Biotherapeutics
- Gouty Arthritis (Gout) – Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- Lesinurad - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- RDEA684 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Ilaris - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- MBX-102 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- PNXXXX - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- BCX4208 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Arcalyst - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Krystexxa - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- PL 4100 Indomethacin - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- NU1618 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Uricase-PEG 20 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Lesinurad + Allopurinol - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Lesinurad + Febuxostat - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- IL1R1 NAM - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- BCX4208 + Allopurinol - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Zoledronate - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- LC350189 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Inflammasome Modulator Program - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- XO Inhibitor - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- MBX-102 + Febuxostat - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- RDEA3170 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- SK-0910 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Program B - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- GoutVax - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- KUX-1151 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Gouty Arthritis (Gout) Therapeutics – Drug Profile Updates
- Gouty Arthritis (Gout) Therapeutics – Discontinued Products
- Gouty Arthritis (Gout) Therapeutics - Dormant Products
- Gouty Arthritis (Gout) – Product Development Milestones
- Featured News & Press Releases
- Jul 30, 2012: Regeneron Pharma Receives Complete Response Letter From FDA For sBLA For ARCALYST Injection
- Jul 24, 2012: BioCryst Pharma Announces Positive Results From Two Ulodesine Phase II Trials In Patients With Gout
- Jul 02, 2012: Analysis Of Savient's KRYSTEXXA Phase III Data Demonstrates Improved Health-Related Quality Of Life And Physical Function In Refractory Chronic Gout Patients
- Jun 06, 2012: BioCryst Presents Results From BCX4208 Gout Program At Annual European Congress Of Rheumatology
- May 17, 2012: Pharmos Successfully Completes Proof-Of-Concept Clinical Trial Of Levotofisopam For Treatment Of Gout
- May 08, 2012: Regeneron Provides Update On FDA Advisory Committee Discussion Of ARCALYST Injection
- Apr 05, 2012: Pharmos Provides Update On Phase IIa Trial Of Levotofisopam For Treatment Of Gout
- Mar 05, 2012: Savient Announces Named Patient Programme For KRYSTEXXA In EU For Patients With Refractory Chronic Gout
- Jan 10, 2012: Pharmos Announces Dosing Of First Patients In Clinical Trial Of Levotofisopam For Treatment Of Gout
- Jan 08, 2012: BioCryst Announces Positive Results From Ongoing BCX4208 Phase IIb Study In Patients With Gout
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products Under Development for Gouty Arthritis (Gout), H2 2012
- Products under Development for Gouty Arthritis (Gout) – Comparative Analysis, H2 2012
- Number of Products under Development by Companies, H2 2012
- Number of Products under Development by Companies, H2 2012 (Contd..1)
- Number of Products under Investigation by Universities/Institutes, H2 2012
- Comparative Analysis by Late Stage Development, H2 2012
- Comparative Analysis by Mid Clinical Stage Development, H2 2012
- Comparative Analysis by Early Clinical Stage Development, H2 2012
- Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012
- Products under Development by Companies, H2 2012
- Products under Development by Companies, H2 2012 (Contd..1)
- Products under Investigation by Universities/Institutes, H2 2012
- Novartis AG, H2 2012
- Kissei Pharmaceutical Co., Ltd., H2 2012
- Savient Pharmaceuticals, Inc., H2 2012
- Addex Pharmaceuticals, H2 2012
- Ardea Biosciences, Inc., H2 2012
- BioCryst Pharmaceuticals, Inc., H2 2012
- SANWA KAGAKU KENKYUSHO CO.,LTD., H2 2012
- Regeneron Pharmaceuticals, Inc., H2 2012
- XOMA Ltd., H2 2012
- LG Life Sciences, Ltd, H2 2012
- Metabolex, Inc, H2 2012
- Wellstat Therapeutics Corporation, H2 2012
- Opsona Therapeutics Ltd., H2 2012
- PLx Pharma Inc., H2 2012
- Nuon Therapeutics, Inc., H2 2012
- Polaris Group, H2 2012
- Eleven Biotherapeutics, H2 2012
- Assessment by Monotherapy Products, H2 2012
- Assessment by Combination Products, H2 2012
- Assessment by Stage and Route of Administration, H2 2012
- Assessment by Stage and Molecule Type, H2 2012
- Gouty Arthritis (Gout) Therapeutics – Drug Profile Updates
- Gouty Arthritis (Gout) Therapeutics – Discontinued Products
- Gouty Arthritis (Gout) Therapeutics – Dormant Products
- List of Figures
- Number of Products under Development for Gouty Arthritis (Gout), H2 2012
- Products under Development for Gouty Arthritis (Gout) – Comparative Analysis, H2 2012
- Products under Development by Companies, H2 2012
- Products under Investigation by Universities/Institutes, H2 2012
- Late Stage Products, H2 2012
- Mid Clinical Stage Products, H2 2012
- Early Clinical Stage Products, H2 2012
- Discovery and Pre-Clinical Stage Products, H2 2012
- Assessment by Monotherapy Products, H2 2012
- Assessment by Combination Products, H2 2012
- Assessment by Route of Administration, H2 2012
- Assessment by Stage and Route of Administration, H2 2012
- Assessment by Molecule Type, H2 2012
- Assessment by Stage and Molecule Type, H2 2012
AbstractGouty Arthritis (Gout) – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Gouty Arthritis (Gout) - Pipeline Review, H2 2012', provides an overview of the Gouty Arthritis (Gout) therapeutic pipeline. This report provides information on the therapeutic development for Gouty Arthritis (Gout), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gouty Arthritis (Gout). 'Gouty Arthritis (Gout) - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope- A snapshot of the global therapeutic scenario for Gouty Arthritis (Gout).
- A review of the Gouty Arthritis (Gout) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Gouty Arthritis (Gout) pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy- Identify and understand important and diverse types of therapeutics under development for Gouty Arthritis (Gout).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Gouty Arthritis (Gout) pipeline depth and focus of Gouty Arthritis (Gout) therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Get full details about this report >>
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
